vs

Side-by-side financial comparison of Energy Recovery, Inc. (ERII) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.

Energy Recovery, Inc. is the larger business by last-quarter revenue ($66.9M vs $65.1M, roughly 1.0× MESA LABORATORIES INC). Energy Recovery, Inc. runs the higher net margin — 40.2% vs 5.6%, a 34.7% gap on every dollar of revenue. On growth, MESA LABORATORIES INC posted the faster year-over-year revenue change (3.6% vs -0.3%). MESA LABORATORIES INC produced more free cash flow last quarter ($18.0M vs $6.4M). Over the past eight quarters, Energy Recovery, Inc.'s revenue compounded faster (8.1% CAGR vs 5.1%).

Energy Recovery Inc. is an American manufacturer of energy recovery devices for water and CO2 refrigeration industries.

Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.

ERII vs MLAB — Head-to-Head

Bigger by revenue
ERII
ERII
1.0× larger
ERII
$66.9M
$65.1M
MLAB
Growing faster (revenue YoY)
MLAB
MLAB
+3.9% gap
MLAB
3.6%
-0.3%
ERII
Higher net margin
ERII
ERII
34.7% more per $
ERII
40.2%
5.6%
MLAB
More free cash flow
MLAB
MLAB
$11.6M more FCF
MLAB
$18.0M
$6.4M
ERII
Faster 2-yr revenue CAGR
ERII
ERII
Annualised
ERII
8.1%
5.1%
MLAB

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ERII
ERII
MLAB
MLAB
Revenue
$66.9M
$65.1M
Net Profit
$26.9M
$3.6M
Gross Margin
67.2%
64.2%
Operating Margin
46.8%
12.2%
Net Margin
40.2%
5.6%
Revenue YoY
-0.3%
3.6%
Net Profit YoY
14.7%
316.6%
EPS (diluted)
$0.49
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ERII
ERII
MLAB
MLAB
Q4 25
$66.9M
$65.1M
Q3 25
$32.0M
$60.7M
Q2 25
$28.1M
$59.5M
Q1 25
$62.1M
Q4 24
$67.1M
$62.8M
Q3 24
$38.6M
$57.8M
Q2 24
$27.2M
$58.2M
Q1 24
$12.1M
$58.9M
Net Profit
ERII
ERII
MLAB
MLAB
Q4 25
$26.9M
$3.6M
Q3 25
$3.9M
$2.5M
Q2 25
$2.1M
$4.7M
Q1 25
$-7.1M
Q4 24
$23.5M
$-1.7M
Q3 24
$8.5M
$3.4M
Q2 24
$-642.0K
$3.4M
Q1 24
$-8.3M
$-254.6M
Gross Margin
ERII
ERII
MLAB
MLAB
Q4 25
67.2%
64.2%
Q3 25
64.2%
61.5%
Q2 25
64.0%
62.0%
Q1 25
61.8%
Q4 24
70.2%
63.3%
Q3 24
65.1%
61.3%
Q2 24
64.6%
64.0%
Q1 24
59.0%
62.1%
Operating Margin
ERII
ERII
MLAB
MLAB
Q4 25
46.8%
12.2%
Q3 25
11.4%
7.8%
Q2 25
5.3%
5.1%
Q1 25
2.4%
Q4 24
38.2%
9.2%
Q3 24
18.3%
6.1%
Q2 24
-7.4%
9.6%
Q1 24
-90.4%
-460.6%
Net Margin
ERII
ERII
MLAB
MLAB
Q4 25
40.2%
5.6%
Q3 25
12.1%
4.1%
Q2 25
7.3%
8.0%
Q1 25
-11.4%
Q4 24
35.0%
-2.7%
Q3 24
22.0%
5.9%
Q2 24
-2.4%
5.8%
Q1 24
-68.3%
-432.2%
EPS (diluted)
ERII
ERII
MLAB
MLAB
Q4 25
$0.49
$0.65
Q3 25
$0.07
$0.45
Q2 25
$0.04
$0.85
Q1 25
$-1.30
Q4 24
$0.40
$-0.31
Q3 24
$0.15
$0.63
Q2 24
$-0.01
$0.62
Q1 24
$-0.14
$-47.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ERII
ERII
MLAB
MLAB
Cash + ST InvestmentsLiquidity on hand
$75.2M
$29.0M
Total DebtLower is stronger
$68.4M
Stockholders' EquityBook value
$206.2M
$186.7M
Total Assets
$231.5M
$434.8M
Debt / EquityLower = less leverage
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ERII
ERII
MLAB
MLAB
Q4 25
$75.2M
$29.0M
Q3 25
$70.4M
$20.4M
Q2 25
$79.5M
$21.3M
Q1 25
$27.3M
Q4 24
$78.0M
$27.3M
Q3 24
$118.6M
$24.3M
Q2 24
$101.0M
$28.5M
Q1 24
$117.4M
$28.2M
Total Debt
ERII
ERII
MLAB
MLAB
Q4 25
$68.4M
Q3 25
$69.4M
Q2 25
$70.3M
Q1 25
$71.3M
Q4 24
$72.2M
Q3 24
$73.1M
Q2 24
$74.1M
Q1 24
Stockholders' Equity
ERII
ERII
MLAB
MLAB
Q4 25
$206.2M
$186.7M
Q3 25
$180.8M
$178.5M
Q2 25
$185.2M
$172.5M
Q1 25
$159.8M
Q4 24
$210.0M
$155.2M
Q3 24
$233.9M
$161.5M
Q2 24
$218.5M
$150.7M
Q1 24
$216.0M
$145.4M
Total Assets
ERII
ERII
MLAB
MLAB
Q4 25
$231.5M
$434.8M
Q3 25
$209.6M
$430.4M
Q2 25
$212.3M
$435.7M
Q1 25
$433.3M
Q4 24
$242.8M
$433.3M
Q3 24
$262.7M
$454.1M
Q2 24
$249.0M
$440.4M
Q1 24
$244.3M
$446.8M
Debt / Equity
ERII
ERII
MLAB
MLAB
Q4 25
0.37×
Q3 25
0.39×
Q2 25
0.41×
Q1 25
0.45×
Q4 24
0.47×
Q3 24
0.45×
Q2 24
0.49×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ERII
ERII
MLAB
MLAB
Operating Cash FlowLast quarter
$7.1M
$18.8M
Free Cash FlowOCF − Capex
$6.4M
$18.0M
FCF MarginFCF / Revenue
9.6%
27.7%
Capex IntensityCapex / Revenue
1.0%
1.1%
Cash ConversionOCF / Net Profit
0.26×
5.17×
TTM Free Cash FlowTrailing 4 quarters
$15.8M
$37.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ERII
ERII
MLAB
MLAB
Q4 25
$7.1M
$18.8M
Q3 25
$-3.1M
$8.2M
Q2 25
$4.1M
$1.9M
Q1 25
$12.7M
Q4 24
$9.0M
$18.1M
Q3 24
$-3.0M
$5.3M
Q2 24
$8.1M
$10.7M
Q1 24
$6.5M
$12.9M
Free Cash Flow
ERII
ERII
MLAB
MLAB
Q4 25
$6.4M
$18.0M
Q3 25
$-3.5M
$7.1M
Q2 25
$4.0M
$884.0K
Q1 25
$11.9M
Q4 24
$8.9M
$17.3M
Q3 24
$-3.2M
$3.5M
Q2 24
$7.9M
$9.9M
Q1 24
$5.7M
$12.3M
FCF Margin
ERII
ERII
MLAB
MLAB
Q4 25
9.6%
27.7%
Q3 25
-10.9%
11.7%
Q2 25
14.3%
1.5%
Q1 25
19.2%
Q4 24
13.2%
27.6%
Q3 24
-8.2%
6.0%
Q2 24
28.9%
16.9%
Q1 24
46.9%
21.0%
Capex Intensity
ERII
ERII
MLAB
MLAB
Q4 25
1.0%
1.1%
Q3 25
1.1%
1.8%
Q2 25
0.5%
1.7%
Q1 25
1.2%
Q4 24
0.2%
1.3%
Q3 24
0.4%
3.1%
Q2 24
0.7%
1.5%
Q1 24
6.8%
0.9%
Cash Conversion
ERII
ERII
MLAB
MLAB
Q4 25
0.26×
5.17×
Q3 25
-0.81×
3.32×
Q2 25
2.02×
0.40×
Q1 25
Q4 24
0.38×
Q3 24
-0.35×
1.54×
Q2 24
3.17×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ERII
ERII

Water Segment$38.6M58%
Other$11.0M16%
Original Equipment Manufacturer$10.6M16%
Aftermarket$6.6M10%

MLAB
MLAB

Sterilization And Disinfection Control$24.9M38%
Biopharmaceutical Development$14.4M22%
Other$14.1M22%
Clinical Genomics$11.8M18%

Related Comparisons